ClinicalTrials.gg
Drug

Irinotecan sucrosofate clinical trials

Also written PEP02 and MM-398.

A product of Irinotecan; its studies count on that page too.

studies test it
79
open now
35
in phase 3
5
first study started
2006

How each study uses irinotecan sucrosofate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the irinotecan sucrosofate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Oct 2015 · ONIVYDE · NDA 207793 (FDA, Drugs@FDA)
European Union
14 Oct 2016 · Onivyde pegylated liposomal (previously Onivyde) · EMEA/H/C/004125 (EMA; as Irinotecan)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Onivyde
15
nal-IRI
14
Irinotecan Liposome
13
Nanoliposomal Irinotecan
12
Irinotecan liposome injection
11

Development codes

PEP02
9
MM-398
9
BAX2398
1

Studies by the year they started

79 studies that test it; most in 2024 (18)

Studies that test irinotecan sucrosofate, by start year
YearStudies
20061
20071
20092
20111
20121
20131
20142
20152
20161
20175
20188
20197
20203
20219
20223
202418
20258
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
25
Phase 2
55
Phase 3
5
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 59

CSPC Ouyi Pharmaceutical Co., Ltd. (5) · PharmaEngine (5) · Ipsen (4) · National Health Research Institutes, Taiwan (3) · Institut de Recherches Internationales Servier (2) · Federation Francophone de Cancerologie Digestive (2) · AIO-Studien-gGmbH (2) · GERCOR - Multidisciplinary Oncology Cooperative Group (2)

Often tested with

Tested in the same studies.

Fluorouracil (21) · Leucovorin (11) · Oxaliplatin (11) · Bevacizumab (7) · Capecitabine (5) · Paclitaxel (3) · Immune checkpoint inhibitors (3) · Trifluridine tipiracil drug combination (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 13

Studies that test irinotecan sucrosofate.

Studies

Open first, then newest update. How each study uses irinotecan sucrosofate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 79

See all 79 studies that test irinotecan sucrosofate →

Given beside what is tested · 26 — irinotecan sucrosofate is usual care or a partner of the new treatment

Showing 20 of 26.

As the comparator · 3 — what is tested is compared with irinotecan sucrosofate

Codes

What other systems call irinotecan sucrosofate · ClinicalTrials.gg INT006367

  • MeSH (NLM) C584112irinotecan sucrosofateOne source NLM
  • UNII (FDA) OL741S3N8BIRINOTECAN SUCROSOFATEConfirmed FDA, NLM, Wikidata
  • Wikidata Q27285712irinotecan sucrosofateConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C82676Irinotecan SucrosofateOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.